Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cyrus Therapeutics

Request full access

Development of small molecule medicines and antibody-drug conjugates (ADCs) targeting previously undruggable cancer targets

Seoul, South KoreaFounded 2019Biotech & Life Sciences

About Cyrus Therapeutics

Cyrus Therapeutics is a clinical-stage biotechnology company specializing in the discovery and development of medicines for chronic and life-threatening diseases, with a particular focus on oncology. The company develops small molecule medicines aimed at "undruggable" cancer targets, a significant area of unmet need in the pharmaceutical industry. Cyrus Therapeutics is also advancing its capabilities in targeted protein degradation and possesses technology for optimizing linkers used in Antibody-Drug Conjugate (ADC) cancer therapies.

The company operates in the biotechnology sector, targeting the global oncology market. Its business model is centered on research and development, with the goal of advancing its drug candidates through clinical trials. As a clinical trial-ready company, Cyrus Therapeutics likely seeks to form strategic partnerships with larger pharmaceutical companies for further development, commercialization, and marketing of its proprietary technologies and drug pipeline. The company

Source: Dealroom company data

At a glance

Status
Operational
Employees
16
Open positions
None listed
Dealroom signal
57.8/100
Industry
Health
Sub-industry
Pharmaceutical, BioTechnology
Sector
Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

2 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES B✓Equity / VC Jan 2022 $24M $97M Mirae Asset Venture Investment · GC Pharma · Atinum Investment · Kolon Investment ↗
SERIES A✓Equity / VC Sep 2020 $8.4M $34M Kolon Investment · Timefolio Asset Management · Paratus Investment ↗
Showing the latest 2 of 2 recorded eventsBook a demo for the full funding history →

Growth signals

Cyrus Therapeutics website traffic

Latest recorded traffic for Cyrus Therapeutics is 4.1K monthly website visits, up 86.4% over the last three months. Cyrus Therapeutics's team grew 0% over the past year.

Latest monthly visits4.1K 3-month web change+86.4% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cyrus Therapeutics in the Seoul ecosystem

Live from Dealroom

The Cyrus Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

6 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A6 investors entered at this stage

  • Kolon Investment
  • Timefolio Asset Management
  • Paratus Investment
  • Mirae Asset Venture Investment
  • GC Pharma
  • Atinum Investment
Team profiled 2 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 2 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇰🇷 South Korea100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cyrus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cyrus Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.